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Aims The cardiomyopathy found in Duchenne muscular dystrophy (DMD) is responsible for death due to heart failure in
30% of patients and additionally contributes to many DMD morbidities. Strategies to bypass DMD-causing
mutations to allow an increase in body-wide dystrophin have proved promising, but increasing cardiac dystrophin
continues to be challenging. The purpose of this study was to determine if therapeutic restoration of cardiac dystro-
phin improved the significant cardiac hypertrophy and diastolic dysfunction identified in X-linked muscular dystrophy
(mdx) dystrophin-null mouse due to a truncation mutation over time after treatment.
Methods
and results
Mice lacking dystrophin due to a truncation mutation (mdx) were given an arginine-rich, cell-penetrating, peptide-con-
jugated phosphorodiamidate morpholino oligomer (PPMO) that delivered a splice-switching oligonucleotide-mediated
exon skipping therapy to restore dystrophin in mdx mice before the development of detectable cardiomyopathy.
PPMO successfully restored cardiac dystrophin expression, preserved cardiac sarcolemma integrity, and prevented
the development of cardiac pathology that develops in mdx-null mice over time. By echocardiography and Doppler
analysis of the mitral valve, we identified that PPMO treatment of mdx mice prevented the cardiac hypertrophy and
diastolic dysfunction identified in sham-treated, age-matched mdx mice, characteristic of DMD patients early in
the disease process, in as little as 5–6 weeks after the initiation of treatment. Surprisingly, despite the short-term
replacement of cardiac dystrophin (,1% present after 12 weeks by immunodetection), PPMO therapy also provided
a durable cardiac improvement in cardiac hypertrophy and diastolic dysfunction for up to 7 months after the initiation
of treatment.
Conclusion These results demonstrate for the first time that PPMO-mediated exon skipping therapy early in the course of DMD
may effectively prevent or slow down associated cardiac hypertrophy and diastolic dysfunction with significant long-
term impact.
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1. Introduction
Duchenne muscular dystrophy (DMD), a lethal and progressive
muscle wasting disorder, is caused by deletions or mutations in
DMD gene, which disrupt the open reading frame and create pre-
mature termination of translation, resulting in the lack of dystro-
phin production. In contrast, Becker muscular dystrophy (BMD),
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a milder form, is caused by the deletions in DMD gene, which main-
tain the open reading frame, resulting in production of internally
deleted but partially functional dystrophin.1 Thus, restoration of
the open reading frame in DMD transcripts by antisense oligonu-
cleotides that mediate targeted exon exclusion should create shor-
tened transcripts, in which the reading frame is restored. These
transcripts then generate truncated, partially functional dystrophin,
which converts severe DMD to a milder BMD phenotype.
The proof of principle for the oligonucleotide-induced modu-
lation of splicing has been convincingly shown in a number cell
culture and in vivo in models of several diseases.2 For DMD in par-
ticular, it was also confirmed in a small clinical trial, in which intra-
muscular injections of exon-skipping, splice switching
oligonucleotides (SSOs) restored dystrophin production.3 In
spite of the progress, effective oligonucleotide delivery to clinically
relevant tissues needs to be improved before SSOs achieve their
therapeutic potential.
The potential of SSO-mediated exon skipping in dystrophin
pre-mRNA has been investigated in primary X-linked muscular
dystrophy (mdx) myoblast cultures4,5 and in the mdx mouse,6 –12
a mouse model of DMD, which carries a nonsense mutation in
exon 23 of the DMD gene, preventing translation of dystrophin
protein. The SSO targeted to a donor splice site of intron 23 or
other splicing elements in exon 23 forces skipping of the exon,
leading to internally deleted dystrophin production. Among oligo-
nucleotide chemistries tested in mdx mice, systemically delivered
phosphorodiamidate morpholino oligomers (PMOs) were particu-
larly effective in exon 23 skipping and dystrophin expression at
therapeutic levels in body-wide skeletal muscles of mdx mice,
which led to functional improvement of skeletal muscles. Unfortu-
nately, induction of exon skipping and dystrophin expression, if any,
in heart was not detectable.11 Since all striated muscles, including
cardiac muscle, are affected by DMD, and 30% of deaths in
DMD patients are caused by heart failure,13 induction of dystro-
phin expression in cardiac muscle is critical for DMD treatment.
We previously reported for the first time that dystrophin
expression was efficiently induced in the heart of mdx mice by
arginine-rich cell-penetrating peptide conjugated PMO (PPMO),
named AVI-5225 carrying (RXRRBR)2XB peptide, where R is argi-
nine, X is 6-aminohexanoic acid, and B is b-alanine.14 Effective
exon skipping and sustained dystrophin expression were achieved
not only in the heart but also throughout the body in skeletal
muscle, leading to improvement in muscle integrity as shown by
a significant decrease of serum creatine kinase (CK). In the
present study, we examined the functional improvement of mdx
cardiomyopathy in response to the efficient restoration of
cardiac dystrophin protein using AVI-5225.
2. Methods
2.1 PPMO conjugates
PPMOs were synthesized and purified at AVI BioPharma (Corvallis,
OR) as previously described by Wu et al.15 The AVI-5225 PPMO, tar-
geted to the 50 splice site of mouse dystrophin intron 23 (50-GGC
CAA ACC TCG GCT TAC CTG AAA T-30), was conjugated to B
peptide (RXRRBR)2XB, where R is arginine, X is 6-aminohexanoic
acid, and B is b-alanine, at the 30-end.14 PPMO 623-25-B, a negative
control, was targeted to unrelated dystrophin human b-globin gene
(50- TGT TAT TCT TTA GAA TGG TGC AAA G-30) and used for
the sham-treated group. Both PPMOs were resuspended and diluted
in sterile normal saline and stored at 48C.
2.2 Experimental animals and PPMO
treatment
All animal experiments were approved by Institutional Animal Care
and Use Committee at the University of North Carolina and
conform to the Guide for the Care and Use of Laboratory Animals
Published by the US National Institutes of Health (NIH Publication
No. 85-23, revised 1996). Age-matched C57BL/10ScSn-Dmdmdx/J
(X-linked muscular dystrophy (mdx)) and C57BL/10ScSnJ (C57BL)
mice were purchased from Jackson Laboratory (Bar Harbor, ME).
Animals were fed chow ad libitum. 0.3 mg per mouse per day
(12 mg/kg) of PPMO conjugate was injected i.v. to 8–16 week-old
mice in two cycles of four once daily injections with a 2-week interval
(Figure 1). A sham PPMO 623-25-B targeted to unrelated, human
b-globin gene was used in the short-term studies (Group 1) while a
saline control was used in the long-term studies (Group 2). Mice
were anaesthetized with isoflurane to the point they were non-
responsive to toe pinch and then euthanized by cervical dislocation.
All 47 mdx and 30 wild-type mice used successfully completed these
studies.
2.3 RNA and protein analysis
The RNA and protein analysis was described in detail previously.14
Briefly, the level of exon 23-skipped transcript was analysed in total
RNA extracted from tissue samples by nested RT–PCR with
primers targeted to exons 21 and 25. The level of dystrophin restor-
ation was evaluated in tissue total protein lysate by in-gel immunode-
tection. NCL-DYS2, a mouse monoclonal antibody against C-terminus
of dystrophin (Novocastra, Newcastle upon Tyne, UK), followed by
IRDye 680-labelled goat anti-mouse IgG (LI-COR Biosciences,
Lincoln, NE), were used. The gel was subsequently analysed by
Odyssey infrared imaging system (LI-COR Biosciences).
An expanded Methods section is available in the Supplementary
material online.
3. Results
3.1 AVI-5225 induced global dystrophin
expression throughout the mdx heart
Systemic delivery of the PPMO AVI-5225, targeted to a donor
splice site of mouse dystrophin intron 23, induces a high level of
exon 23 skipping and sustained dystrophin expression body-wide
in striated muscles, importantly in the cardiac muscle of the dys-
trophic X-linked muscular dystrophy (mdx) mouse.14 We there-
fore determined whether the induced dystrophin protein could
produce functional benefit on the heart of AVI-5225-treated mdx
mice.
mdx mice were treated with AVI-5225 by two cycles of four
once daily IV injections at 12 mg/kg/day with a 2-week interval as
outlined in Figure 1 (Group 1). Six weeks after the initiation of
therapy, high levels of exon skipping and dystrophin induction
were achieved extensively in all skeletal, smooth, and cardiac
muscles (Figure 2 and data not shown). In the heart, the level
of exon 23-skipped transcript determined by nested RT–PCR
was about 80–90%, while no skipping product was observed in
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sham-treated mdx mice, injected with the sham PPMO 623-25-B
targeted to unrelated, human b-globin gene, or in wild-type
C57BL mice (Figure 2A). The level of restored dystrophin protein
in the hearts of AVI-5225-treated mdx mice analysed by in-gel
immunodetection was about 30% of wild-type mice at 3 weeks
after the last injection (Figure 2B). Immunofluorescence detection
of dystrophin on heart sections showed that AVI-5225-induced
dystrophin was expressed entirely throughout the heart of
treated mdx mice and was properly localized at the sarcolemma
of cardiac muscles (Figure 2C). As expected, no detectable dystro-
phin expression was observed in sham-treated mdx mice.
3.2 Rescued dystrophin in the mdx heart
improved sarcolemma integrity
A lack of dystrophin in muscles of mdx mice and DMD patients
results in plasma membrane instability and increased membrane
permeability leading to leakage of intracellular contents into
blood circulation.16,17 Serum CK and CK-MB isoenzyme are two
hallmarks for membrane instability of whole-body muscles and
heart specific muscle, respectively. As expected with increasing
muscle damage, we identified that serum total CK (Figure 2D)
and cardiac CK-MB (Figure 2E) increased with time in sham-treated
mdx mice compared to wild-type controls. Both serum CK and
cardiac CK-MB returned to wild-type levels in AVI-5225-treated
mdx mice 5 weeks after the initiation of therapy (Figure 2D, E).
We previously demonstrated that AVI-5225 treatment induces
persistent increases in rescued dystrophin expression for up to
at least 11 weeks after the last injection, after which it is no
longer present in the heart.14 These results indicate that the sarco-
lemma of whole-body muscles was stabilized and that cardiac
damage was significantly reduced by rescued dystrophin.
3.2.1 Rescued dystrophin prevents cardiac hypertrophy
and inhibits diastolic dysfunction that develops in mdx
mice at ages 16–21 weeks (Group 1)
Increased cardiac mass and diastolic dysfunction has been consist-
ently identified in the mdx model of DMD.18– 20 To determine
how therapy could help prevent the natural history of mdx cardi-
omyopathy, we analysed function at baseline (16 weeks of age)
and 5 weeks after the initiation of therapy (21 weeks of age).
Figure 1 Treatment regimen of PPMOs in mdx mice. Age-matched mdx mice were treated with AVI-5225 or the sham PPMO 623-25-B for
two cycles of four once daily i.v. injections at 12 mg/kg/day. Two groups were studied to determine short-term effects of AVI-5225 therapy on
the development or mdx cardiomyopathy (Group 1, top) and the long-term effects of AVI-5225 therapy (Group 2, bottom). The effects of
short-term treatment were determined at 5 and 6 weeks after the initiation of treatment (Group 1, top). Long-term effects were determined
after 7 months after the initiation of treatment (Group 2, bottom). Serum was collected at indicated time points to monitor the level of
creatine kinase (CK) and CK-MB isoenzyme. RNA, protein. Histology of cardiac muscle was analysed 6 weeks after the initiation of therapy.
Cardiac metrics mice were analysed by echocardiography (Echo) and Doppler analysis at baseline, 5 weeks (Group 1), or 28 weeks
(Group 2) after the initiation of therapy. *Echo and Doppler measurements were performed on independent age-matched mice and compared
with those measured at later timepoints.
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Figure 2 Global dystrophin expression in the heart of mdx mice induced by PPMO AVI-5225 prevents the loss of sarcolemma integrity 6
weeks after the initiation of therapy. (A) The level of exon 23-skipped mRNA was analysed by nested RT–PCR 3 weeks after the last injection.
The upper band (445 bp) indicated by FL corresponds to the full-length dystrophin transcript, and the lower band (232 bp) indicated by D23
corresponds to the exon 23-skipped dystrophin transcript. The percentages of exon 23 skipping are shown. Samples A and B are from different
mice. (B) In-gel western detection of total protein extracted from injected mdx heart. Dystrophin (DYS) was detected by the NCL-DYS2 mono-
clonal antibody. The percentages of dystrophin restoration compared with the average of two different wild-type mice are shown. (C) Immuno-
fluorescence detection of dystrophin in the treated mdx heart 6 weeks after the start of therapy. Panels 1–4 are higher-magnification images of
the regions shown in the full-view image of the AVI-5225- treated heart. Panel 1: septum; 2: anterior left ventricle wall (LV); 3: posterior LV; 4:
lateral LV. C57BL: heart from normal C57BL mouse; Sham-treated: heart from PPMO 623-25-B-treated mdx mouse. Scale bar, 100 mm. Sig-
nificantly less serum CK (D) and CK-MB (E) is circulating in mdx mice after AVI-5225 treatment compared with age-matched mdx sham-treated
controls. C57BL (n ¼ 10), Sham-treated mdx mice (n ¼ 11), and AVI-5225-treated mdx mice (n ¼ 6). A one-way ANOVA was performed to
determine significance, followed by a Holm-Sidak pairwise comparison to significance between groups, *P , 0.05 for comparisons to wild-type
C57BL; †P , 0.05 for comparisons to sham-treated mdx mice.
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High-resolution echocardiography was performed on conscious
wild-type, sham-treated mdx mice, and AVI-5225-treated mdx
mice to determine the efficacy of SSO treatment on these funda-
mental cardiac defects (Figure 3 and Table 1). By a multiple tests
and measures, we identified that SSO treatment significantly
improved the status and function of the heart in mdx mice.
Sixteen-week-old mice just prior to the development of the mdx
cardiomyopathy were used to assess short-term PPMO therapy
(Figure 3). Pre-treatment, mdx hearts did not differ from age-
matched wild-type controls (Table 1, Figure 3A,B). No significant
differences in wall thickness, systolic function (Table 1, Figure 3A),
or diastolic function (Figure 3B) were identified at baseline before
treatment. Five weeks after the induction of therapy (age
21 weeks), we identified that sham-treated mdx mice had signifi-
cant increases in anterior and posterior wall thicknesses in both
diastole and systole (AWTD/AWTS and PWTD/PWTS, respect-
ively, in Table 1), represented in M-mode images (Figure 3C). Five
weeks after the initiation of PPMO AVI-5225 therapy, mdx mice
demonstrated a wall thickness nearly equivalent wild-type controls
and baseline levels (Table 1), indicating that therapy prevented
cardiac hypertrophy. This striking response to therapy is consistent
with our previous study, which demonstrated increased cardiac
dystrophin to 5% of wild-type level in as little as one day after
the four AVI-5225 daily injections.14 Persistent splicing correction
of cardiac dystrophin has been identified for a maximum of
11 weeks using this treatment (Day 1 90% correction; 11
weeks 1–2% correction).14 With the significant replacement of
dystrophin by PPMO-treatment in these short-term experiments,
we identified the nearly complete resistance against the
mdx-associated cardiomyopathy if PPMO-therapy is given before
characteristic phenotypic increases in cardiac mass and diastolic
function occur.
Consistent with an increase in wall thickness determined by
echocardiography, we identified an increase in echocardiography
determined left-ventricular mass (LV mass) in mdx mice compared
to wild-type mice (Figure 3D). This increase in cardiac mass was
also identified by weighing the histologically fixed heart samples
before processing. In mdx mice treated with AVI-5225 therapy,
increased heart weight was not identified, and was nearly equival-
ent to age matched wild-type animals (Table 1). Likewise, 5 weeks
after the initiation of treatment, both heart weight and LV mass/
body weight ratio determined by echocardiography (Figure 3D)
were significantly less compared with sham treated mdx controls
and comparable to age-matched wild type mice.
We identified that sham-treated mdx hearts had increased car-
diomyocyte cross-sectional areas (Figure 3F, middle), compared
with wild-type (Figure 3F, left) and AVI-5225-treated animals
(Figure 3F, right), indicative of cardiac hypertrophy. Quantitatively,
sham-treated mdx mice had a 63% increase in cross-sectional
area (Figure 3G). In AVI-5225-treated animals, only small increases
(16%) in cardiomyocyte cross-sectional area was identified com-
pared with wild-type age-matched controls (Figure 3G). Histologi-
cally, rare patchy areas of fibrosis could be detected in both
sham- and AVI-5225-treated mdx mice (Figure 4C–F ), suggesting
that improvements in cardiac hypertrophy and diastolic function
were independent of improvements in the mild extracellular
matrix changes. These studies demonstrate that the phenotype
of cardiac hypertrophy and diastolic dysfunction we identified in
21-week-old mdx mice is significantly attenuated to nearly baseline
levels after 5 weeks of treatment with the SSO.
A common method to identify diastolic function of the heart
is the use of Doppler echocardiography to measure blood
flow through the mitral valve. The E and A waveforms generated
allow the determination of function by measuring the relative
amount of flow through the mitral valve during systole and dia-
stole. A decrease in the E/A ratio is a common marker of diastolic
dysfunction that is identified in boys with DMD.21 Therefore,
Doppler analysis of the mitral valve was performed to determine
if SSO treatment improved diastolic function observed as an
increase in the E/A wave ratio. Diastolic dysfunction was not
observed at baseline 16-week-old mice (Figure 3B). While the dias-
tolic function was not significantly decreased compared with wild-
type controls, one mouse demonstrated inverted E/A waves (0.3),
which decreased the overall mean (Figure 3B). This likely rep-
resents early subtle disease in a single mouse. Confirming previous
observations that mdx mice have diastolic dysfunction early in
life,20,22 we identified that sham-treated mdx mice had a significant
reduction in the E/A wave ratio compared with wild-type control
mice by 21 weeks of age (Figure 3E), indicative of diastolic dysfunc-
tion. In contrast, age-matched PPMO AVI-5225-treated mdx mice
had cardiac function comparable to age-matched wild-type
hearts (Figure 3E), consistent with previous studies of normal E/A
ratios in healthy mice.23 This indicates SSO treatment prevents
the mdx age-associated development of diastolic dysfunction if
given prior to its development.
3.2.2 Rescue of dystrophin results in long-term reduction
in cardiac hypertrophy 7 months after the initiation of
therapy (Group 2)
To determine the durability of the improvements in cardiac func-
tion induced by AVI-5225 treatment, we performed high-
resolution echocardiography on conscious mice at baseline and
after 34 weeks of age ( 7 months) after the initiation of SSO
treatment (Table 1). As dystrophin replacement using AVI-5225
gives detectable levels of functional protein for up to 11 weeks,
AVI-5225 treated mice did not have dystrophin for over 4
months (17 weeks) in these long-term studies. The development
of some cardiac hypertrophy in AVI-5225 treated mdx mice is evi-
denced by significant increases in anterior and posterior wall thick-
nesses (Table 1, Figure 3H) and cardiac LV mass/body weight ratios
(Figure 3I). However, hypertrophy was significantly less than age-
matched saline-treated mdx controls. As would be expected,
these measures were not as close to wild-type controls as seen
in the Group 1 short-term studies (Figure 3H– J ) and were
greater than measurements taken at baseline (Figure 3B, Table 1).
The reduced cardiac hypertrophy in AVI-5225 treated mdx mice
was paralleled by small, but not statistically significant improvement
in diastolic function determined by E/A ratio (Figure 3J). Since the
presence of rescued dystrophin expression is limited to
11 weeks,14 these data suggest that transient expression of sus-
tained dystrophin before the development of mdx cardiomyopathy
is sufficient to maintain improvement and slow progression of mdx
cardiomyopathy.
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Figure 3 Treatment of mdx mice with AVI-5225 prevents the development of mdx-associated cardiac hypertrophy and diastolic dysfunction,
which leads to significant improvements in long-term durability. No differences in cardiac wall thickness shown by representative M mode (A) or
diastolic function determined by mitral valve Doppler analysis (E/A ratio) (B) are present in mdx and wild-type control mice at ages 8 or 16
weeks old. n.s. ¼ not significant. (C) AVI-5225 treatment prevents the development of anterior and posterior wall thickening in mdx mice
as evidence by representative M-mode; (D) LV Mass determined by echocardiography, *P , 0.001 vs. wild type; †P , 0.001 vs. sham-treated
mdx mice; and (E) prevents the development of diastolic dysfunction in mdx hearts determined by mitral valve Doppler analysis, *P , 0.05 vs.
wild-type; †P , 0.05 vs. sham-treated mdx. (F) Representative cross sectional micrographs of wild-type (left, n ¼ 3), sham-treated mdx (middle,
n ¼ 3), and AVI-5225-treated mdx mice (right, n ¼ 3) hearts, illustrating that cardiomyocytes from AVI-5225-treated mdx mice do not develop
cardiomyocyte hypertrophy 5 weeks after the initiation of therapy. Arrows indicate representative cross-sectional areas. Scale bar, 10 mm. (G)
Quantitative analysis of cardiomyocyte cross-sectional areas demonstrates this protection. n ¼ 3 mice/group; each mean is calculated from 50
measurements from multiple sections from the three representative mice from each group. *P , 0.001 vs. wild-type; †P , 0.001 vs. sham-
treated mdx mice. (H ) Durable improvement in mdx mice 7 months after AVI-5225 was identified by reduced anterior and posterior wall
thickening as evidenced by representative M-mode; (I ) LV mass determined by echocardiography, *P , 0.05 vs. wild-type; †P , 0.01 vs. sham-
treated mdx. (J ) Residual improvement in diastolic dysfunction determined by mitral valve Doppler analysis was identified as not statistically
significant between wild-type or sham-treated mdx groups. *P , 0.05 vs. wild-type. A one-way ANOVA was performed to determine signifi-
cance, followed by a Holm-Sidak pairwise comparison to significance between groups, with comparison groups identified above.
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Table 1 High-resolution transthoracic echocardiography was performed on conscious on sham-treated, AVI-5225-treated mdx, and age-matched wild-type control
mice at pre-treatment, 5 weeks of therapy, and 6 months after last treatment as described in Figure 1 (+SE)
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baseline 16
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mdx n 5 9, 7 months
after Rx initiation
BW (g) 22.4+ 0.6 25.4+ 0.7 25.7+ 0.4 27.9+ 0.5 27.4+ 0.4 21.3+ 0.2 22.0+ 0.5 27.2+ 0.7 29.9+ 0.5 28.8+ 0.6
LV mass index
(mg)





















ND ND ND ND ND
HR (b.p.m.) 625.0þ12.9 672.8þ14.6 632.4+ 9.7 624.1+ 9.3 645.7+ 10.6 632+ 12.9 593.2+ 49.5 633.9+ 10.1 647.8+ 13.0 621.4+ 8.8
AWTD (mm) 0.99þ0.01 1.01þ0.02 0.99+ 0.01 1.30+ 0.01* 1.04+ 0.01*,† 0.99+ 0.02 1.01+ 0.02 0.98+ 0.01 1.35+ 0.03* 1.14+ 0.02*,†
AWTS (mm) 1.61þ0.03 1.63þ0.02 1.72+ 0.02 1.87+ 0.03* 1.63+ 0.03† 1.61+ 0.03 1.74+ 0.10 1.62+ 0.03 1.93+ 0.06* 1.75+ 0.06†
PWTD (mm) 0.97þ0.01 0.98þ0.01 0.98+ 0.01 1.24+ 0.02* 1.03+ 0.02† 0.95+ 0.01 0.95+ 0.01 0.94+ 0.02 1.14+ 0.03* 1.10+ 0.03*
PWTS (mm) 1.54þ0.03 1.57þ0.02 1.59+ 0.04 1.77+ 0.04* 1.52+ 0.03† 1.42+ 0.02 1.42+ 0.04 1.58+ 0.03 1.69+ 0.03* 1.59+ 0.04†
LVEDD (mm) 2.87þ0.09 2.91þ0.05 2.68+ 0.05 2.69+ 0.06 2.87+ 0.08 2.77+ 0.11 2.70+ 0.12 2.79+ 0.08 2.93+ 0.09 2.79+ 0.08
LVESD (mm) 1.25þ0.05 1.27þ0.03 1.19+ 0.03 1.21+ 0.03 1.23+ 0.02 1.22+ 0.05 1.15+ 0.06 1.26+ 0.04 1.29+ 0.06 1.25+ 0.06
FS% 56.3þ0.8 56.3þ1.1 55.4+ 0.6 54.9+ 0.7 53.5+ 0.7 55.9+ 0.7 57.1+ 1.2 55.0+ 0.6 55.3+ 0.7 55.2+ 1.3
EF% 87.9þ0.6 87.8þ0.8 87.4+ 0.4 87.0+ 0.5 85.8+ 0.5 87.6+ 0.5 86.3+ 5.9 87.0+ 0.5 87.0+ 0.6 86.9+ 1.1
BW, body weight; HR, heart rate; LV mass index [(ExLVD3d 2 LVED3d)  1.055]; ExLVD, external left-ventricular diameter; b.p.m., heart beats per minute; AWTD, anterior wall thickness in diastole; AWTS, anterior wall thickness in systole;
PWTD, posterior wall thickness in diastole; PWTS, posterior wall thickness in systole; LVEDD, left-ventricular end-diastolic dimension; LVESD, left-ventricular end-systolic dimension; FS, fractional shortening, calculated as (LVEDD 2 LVESD)/
LVEDD  100; EF%, ejection fraction calculated as (end Simpson’s diastolic volume—end Simpson’s systolic volume)/end Simpson’s diastolic volume * 100; ND, not determined; SND, statistics not determined as n ¼ 2.
*P , 0.01 vs. wild-type.







Skipping of exon 23 in dystrophin pre-mRNA and consequent res-
toration of dystrophin protein induced by the PPMO AVI-5225
prevented the disruption in cardiac sarcolemma integrity, cardiac
hypertrophy, and the diastolic dysfunction in X-linked muscular
dystrophy (mdx) mouse hearts. This was identified by histology,
echocardiography, and Doppler analysis. Furthermore, we found
that this transient replacement in dystrophin by AVI-5225
therapy attenuated the long-term onset and progression of
cardiomyopathy.
These results were affected by a conjugate of arginine-rich cell
penetrating peptide B to morpholino oligomer at relatively low
dose of 0.3 mg per mouse (12 mg/kg). The key to the effectiveness
of this compound appears to be the combination of a positively
charged peptide with neutral oligomers that target pre-mRNA in
a sequence specific manner.14,15,24,25 Similar peptides conjugated
to negatively charged oligonucleotide were totally ineffective
(data not shown). The importance of the B peptide is underscored
by previous findings with unconjugated morpholino oligomer or
2’-O-methyl oligonucleotides in the same mdx mouse model.
These unconjugated morpholino compounds restored dystrophin
in skeletal muscles but not in the heart. Furthermore, much
higher doses (up to 100 mg/kg) were required.8,11 Since cardio-
myopathy is one of the causes of death in patients with DMD,
therapies restricted to skeletal muscles are not adequate and para-
doxically lead to the acceleration of cardiomyopathy in mouse
models.26 Improvement of DMD cardiomyopathy in the mdx
mouse was also accomplished by gene therapy methods systemi-
cally delivering microdystrophin gene or antisense RNA using
adeno-associated virus (AAV) as a vector.27–31 The advantage of
the current approach is that it is more akin to standard pharmaco-
logical treatment and therefore amenable to US Food and Drug
Administration (FDA) accepted drug development pathway.
In the present study, we applied PPMO AVI-5225 therapy to
mdx just prior to the development of detectable mdx cardiomyo-
pathy. The application of PPMO AVI-5225 therapy to mdx mice
resulted in the persistent splicing correction of dystrophin in the
heart to levels nearing 79–91% (Figure 2A). Previously, this
AVI-5225 correction was shown to be present by PCR for a
maximum of 11 weeks (1–2% correction); protein was undetect-
able by 12 weeks.14 By treating mdx mice with AVI-5225 to replace
dystrophin just prior to the development of cardiac hypertrophy
and diastolic dysfunction, we were able to prevent these changes
from occurring in the short term when the protein would still
be detectable as shown in our Group 1 studies. That as little of
30% replacement of the dystrophin (Figure 2B) was so effective
may be due to the uniformity of dystrophin protein expression
throughout the heart (Figure 2C) in the absence of any inflamma-
tory response as previously detailed.14,32 After treatment with
Figure 4 Treatment of mdx mice 6 weeks after the initiation of therapy does not alter the mild rare focal fibrosis. Representative heart sec-
tions from wild-type (A and B), sham-treated mdx (C and D), and AVI-5225-treated mdx (E and F ) mice were analysed after Trichrome (A, C, E)
or H&E (B, D, F) staining (20). While rare focal fibrosis is present in both mdx and AVI-5225-treated mdx mice, all three groups of mice are
generally indistinguishable by histology.
Morpholino oligomers improve mdx cardiomyopathy 451
the same peptide-coupled oligonucleotides used in the present
study, no detectable antibodies were detected by ELISA.32 Histo-
logic analysis of tissues from these mice confirmed a lack of inflam-
matory cells.32 Similarly, in the present study we did not identify
any toxicity determined grossly by our observation that there
was no morbidity or mortality throughout the course of the
study. If these effects can be recapitulated in patients, drug treat-
ment may be relatively infrequent and it can be anticipated that
low levels of restored dystrophin will be sufficient to be thera-
peutic. This is further supported by clinical observations that
BMD patients with levels of dystrophin as low as 20% of normal
have relatively mild disease course.33,34
What was surprising in the present study, was that AVI-5225
therapy given to mice followed for up to 7 months after the
initiation of therapy resulted in long-term improvements in
cardiac hypertrophy and diastolic function compared with saline-
treated mdx mice, a time point 7 weeks after the replaced dys-
trophin would have been gone. These findings suggest that even
transient replacement of dystrophin can significantly slow the
progression of mdx-cardiomyopathy, but that continued replace-
ment may be necessary for the progression to be completely
attenuated. The effect of replacing dystrophin in established
mdx-cardiomyopathy has yet to be determined.
In the present study, PPMO treatment to replace dystrophin
ameliorated the development of cardiac hypertrophy determined
by heart weight/body weight, LV mass/body weight, cardiomyocyte
cross-sectional areas, and echocardiography analysis seen in mdx
mice by 21 weeks of age. Dystrophin replacement also improved
diastolic dysfunction, indicating a protection against the sequelae
of pathologic cardiac hypertrophy. Previous reports have identified
spontaneous cardiac hypertrophy in 29 week18 and
10-month35-old mdx mice. Consistent with our identification of
cardiac hypertrophy developing at 16–21 weeks, recent studies
have identified that 8 week mdx mice do not have cardiac hyper-
trophy18 and that cardiomyopathy is present at 16 weeks.30
No previous study to our knowledge has identified the develop-
ment of cardiac hypertrophy in mdx mice at 16–21 weeks,
making this a novel clinical endpoint to study when testing DMD
therapeutics in the mdx mouse.
A recent study by Wu et al.32 likewise found improvement in
diastolic function using the same PPMO treatment to restore
cardiac dystrophin. Since the cardiac wall thickness was not inves-
tigated, this previous study did not identify the significant improve-
ments in cardiac hypertrophy detailed here. Furthermore, we did
not observe systolic defects in mdx cardiac function as Wu
et al.32 did, which is consistent with other investigators determi-
nation of function on conscious mice.18– 20
In clinical application, the effectiveness of PPMO therapy will
depend on the efficiency with which the dystrophin protein is
restored in each DMD patient. Clinical heterogeneity of the
DMD cardiomyopathy in patients indicates that the course of
disease is mutation dependent.36 Considering that the DMD
gene contains 79 exons and that mutations are detected through-
out the gene, therapy may appear a daunting task, especially since
exon skipping approach is sequence specific. However, it has been
well established that a majority of DMD causing deletions are clus-
tered around a hot spot exon 45–55 region. Analysis of deletion
structure and frequency indicates that 5 SSOs targeted to exons
in this region would provide treatment for over 50% of DMD
patients. A single drug skipping exon 51 should be therapeutic
for close to 20% of DMD deletion patients.37
It is anticipated that PPMO therapy would be initiated early in
disease, and that, as in the present study, long-term efficacy may
be achieved in younger children with DMD or in young adults
before the establishment of significant cardiomyopathy. It is plaus-
ible that treatment of early dysfunction of boys with DMD, preced-
ing the onset of dilated cardiomyopathy, may not only improve
their current disease, but also protect against the development
of systolic dysfunction and/or dilated cardiomyopathy.21 The effec-
tiveness of PPMO therapy in more advanced disease remains to be
tested. Because the mdx mouse does not progress to a lethal stage
of disease, it would not be an adequate model for these studies,
such as canine models of disease.38,39
A limitation to the current study is that age-matched untreated
or saline-injected mdx mice were not used for Group 1 mice
where hypertrophy was identified in 21 weeks old sham-oligo
treated mice. The rapid hypertrophy related to the sham-oligo
treatment cannot be completely ruled out, although cardiomyo-
pathic changes have previously reported in young mdx mice this
same age.30
Systemic administration of AVI-5225 restored dystrophin
expression in skeletal muscle throughout the body, including dia-
phragm and cardiac muscle.14 This not only holds great therapeutic
potential for the treatment of DMD, but also genetic cardiac dis-
eases, such as familial hypertrophic cardiomyopathy, which affect
as many as 1 in 500 people.40 Like DMD, these diseases affect chil-
dren and adolescents and are due in part to truncation mutations
of sarcomere proteins. Having the ability to improve the high
prevalence of sudden cardiac death in FHC may prove ground
breaking. Currently, two clinical trials are being conducted in
DMD patients by using 20O-methyl phosphorothioate3 and PMO
(http://clinicaltrials.gov/ct2/show/
NCT00159250?term=DMD&rank=5) to induce skipping of human
dystrophin exon 51 restoring the in-frame transcript. Although the
PPMO-B AVI-5225 showed great promising for clinical application,
FDA mandated safety studies are required before this compound
enters clinical trials.41
The mdx cardiomyopathy is a model of progressive disease, with
younger mice at the ages used in this study showing few histologic
changes,18 increased cardiac mass, and diastolic dysfunction.18 –20
Similarly, patients with DMD can develop cardiac hypertrophy
early in the course of their disease42 and diastolic dysfunction is
a distinct finding in DMD-associated cardiomyopathy.43– 45
AVI-5225 may provide a therapeutic approach to prevent and
sustain the development of DMD cardiomyopathy by systemati-
cally replacing functional dystrophin to both skeletal muscle and
heart to reduce the associated long-term morbidity and mortality.
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online.
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